A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06804103 IN PATIENTS WITH HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2) POSITIVE SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs PF-06804103 (Primary)
- Indications Breast cancer; Gastric cancer; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Pfizer
- 27 Aug 2019 Planned number of patients changed from 95 to 124.
- 02 May 2019 Planned End Date changed from 22 Jun 2021 to 14 Sep 2021.
- 02 May 2019 Planned primary completion date changed from 22 Jun 2021 to 14 Sep 2021.